ISSN: 2574 -1241



Results of Endovascular Treatment of Superior and Inferior Vena Cava at Mid-Term Follow-Up (Up to 65 Moths)

Iveta Tasheva* and Lubomir Dosev

Hospital SofiaMed, Sofia University, Bulgaria

*Corresponding author: Iveta Tasheva, PhD, Hospital SofiaMed, Sofia University, Bulgaria

ARTICLE INFO

Received: 🛗 August 28, 2023

Published: i October 26, 2023

Citation: Iveta Tasheva and Lubomir

Dosev. Results of Endovascular Treat-

ment of Superior and Inferior Vena

Cava at Mid-Term Follow-Up (Up to 65 Moths). Biomed J Sci & Tech Res 53(3)-

2023. BJSTR. MS.ID.008411.

ABSTRACT

Aim: The aim of this study is to report our experience in endovascular treatment of superior and inferior vena cava syndrome.

Methods: Between June 2013 and August 2019, 52 patients (mean age 54.75 years; minimum 20yo, maximum 81yo) were endovascularly treated with self-expandable stents of stenosed superior (78.8% - 41 pts) or inferior (21.2% - 11 pts) vena cava. All patients presented with vena cava obstruction syndrome. Complete occlusion was found in 30.8% - 16pts and mean percent of stenosis was 89.92%. The two main causes of the caval obstructions were carcinoma (82.7%, 43pts) and thrombophilia (7.7%, 4 pts) (Figure 1).



Introduction

- Treatment and complications Successful procedures were 97.8%.
- Balloon predilataion.

- Stent placement self expandable stents (Sinus XL, Protégé, Abre).
- Balloon postdilation.
- Two major complications (3.8%).
- Thrombus migration causing pulmonary embolism (Figure 2).



Figure 2: Epidemiology.

Both of them treated endovascularly with thrombus fragmentation, local fibrinolysis and aspiration. In nearly all patients stents were placed (97.8%) and there was clinical improvement of the caval syndrome- considerable reduction of edema and symptom relief in the treated patients. Of all 52 procedures we had two major intra-procedural complications (3.8%) – both migration of thrombus material causing pulmonary embolism, which was treated with intrapulmonary thrombus fragmentation and thrombolysis. All patients were clinically followed-up; 59.6% were followed-up by CT scan or flow Doppler ultrasound up to 65 months after procedure, with a median follow up period of 1 month (30-1950 days). Stent patency was 93.5% (29 pts); significant stent restenosis or occlusion were found in 2 cases (6.5%) and were successfully treated endovascularly (Figure 3).

Results

- All patients had relief of vena cava syndrome.
- All patients were clinically followed up up to 65 months.
- Median follow up period was 1 month (30-1950 days).
- CT scan or Doppler ultrasound follow up was done in 59.6% of patients (Figure 4) [1-4].



Figure 3: Most of the patients had carcinoma (lung, pancreatic, mediastinal) with most of them with short life expectance and the procedure was palliative to ameliorate the cava syndrome.



Conclusion

Endovascular treatment with stent implantation for superior and inferior vena cava syndrome is a minimal invasive and safe procedure with favorable clinical effect and satisfactory mid-term result.

References

- 1. Petrov I, Tasheva I (2018) UMBAL Ajibadem City Clinic. Cardiovascular Center, Sofia, Bulgaria.
- 2. Zimmerman S, Davis M (2018) Rapid Fire: Superior Vena Cava Syndrome. Emerg Med Clin North Am 36: 577-584.
- 3. Carmo J, Santos A (2018) Chronic Occlusion of the Superior Vena Cava. N Engl J Med 379: 2.
- 4. Nakano T, Endo S, Kanai Y, Otani S, Tsubochi H, et al. (2014) Surgical outcomes after superior vena cava reconstruction with expanded polytetrafluoroethylene grafts. Ann Thorac Cardiovasc Surg 2: 310-315.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2023.53.008411

Iveta Tasheva. Biomed J Sci & Tech Res

(i) (i) This work is licensed under Creative (cc)SA BY

Submission Link: https://biomedres.us/submit-manuscript.php

Commons Attribution 4.0 License



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access •
- **Rigorous Peer Review Process** •
- Authors Retain Copyrights ٠
- Unique DOI for all articles ٠

https://biomedres.us/